Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Operations | December 18, 2023 | December 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date December 18, 2023 · Filed December 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,469 |
Reported balance
After 2023-12-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-18 · Disposition to issuer · Disposed 1,675 · Balance 58,469 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 50,680 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,340 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 50,680 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,340 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 36,099 |
Reported balance
After 2020-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-11 · Other · Disposed 6,412 · Balance 36,099 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 6,412 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2: Includes 16,398 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 19,701 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 17,909 |
Reported balance
After 2020-11-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 18,190 · Balance 17,909 F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4: Includes 16,398 Shares issuable upon vesting of the Wright RSUs and 1,511 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 17,909 · Balance 0 F5: See Exhibit 99.1. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 14,462 |
Reported balance
After 2020-11-11 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2020-11-11 · Grant · Acquired 14,462 · Balance 14,462 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2020-11-11 · Disposition to issuer · Disposed 14,462 · Balance 0 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-11 · Disposition to issuer · Disposed 22,241 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-11 · Disposition to issuer · Disposed 57,153 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 6,412 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
F2: Includes 16,398 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 19,701 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.
F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer.
F4: Includes 16,398 Shares issuable upon vesting of the Wright RSUs and 1,511 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.
F5: See Exhibit 99.1.
F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2023 Filed Dec 19, 2023 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,675 | $121.85 | $204,099.25 |
DisclosureSEC source: 0001093557-23-000252 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,469 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 50,680 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,340 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 19, 2023 Filed Nov 21, 2023 00:26 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,106 | $104.06 | $427,282.68 |
DisclosureSEC source: 0001093557-23-000229 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,144 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,024 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,208 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 08, 2023 Filed Nov 8, 2023 21:05 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,019 | $95.22 | $192,249.18 |
DisclosureSEC source: 0001093557-23-000224 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,250 F1 · shares: On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| July 10, 2023 Filed Jul 10, 2023 21:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,989 | $128.05 | $254,691.45 |
DisclosureSEC source: 0001093557-23-000162 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,269 F1 · shares: On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 22:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,214 | $124.50 | $275,643.00 |
DisclosureSEC source: 0001093557-23-000109 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,258 F1 · shares: On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,010 | $106.27 | $213,602.70 |
DisclosureSEC source: 0001093557-23-000081 · edgardoc.xml · nonDerivative · entry 3 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,472 F3 · shares: On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,274 | $111.40 | $364,720.33 |
DisclosureSEC source: 0001093557-23-000081 · edgardoc.xml · nonDerivative · entry 2 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,482 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,406 | $111.40 | $268,025.99 |
DisclosureSEC source: 0001093557-23-000081 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,756 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:01 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 18,776 | $0.00 | $18.78 |
DisclosureSEC source: 0001093557-23-000059 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,162 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 62,632 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,213 | $106.12 | $234,843.56 |
DisclosureSEC source: 0001093557-23-000016 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,386 F1 · shares: On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 57,172 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,781 | $112.62 | $425,817.73 |
DisclosureSEC source: 0001093557-22-000178 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,599 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 57,172 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 21:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,106 | $500.00 | $553,000.00 |
DisclosureSEC source: 0001093557-22-000078 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,345 F1 · shares: On September 14, 2021, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,345 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 661 | $406.06 | $268,403.48 |
DisclosureSEC source: 0001093557-22-000052 · edgardoc.xml · nonDerivative · entry 2 Regan Barry J. · CIK 0001746313 · EVP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,451 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,345 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:27 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 4,984 | $0.00 | $4.98 |
DisclosureSEC source: 0001093557-22-000052 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,112 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 16,345 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:39 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 1,671 | $0.00 | $1.67 |
DisclosureSEC source: 0001093557-21-000286 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,128 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock. F2 · balance_after: Included in this number are 13,128 unvested restricted stock units, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,214 | $563.93 | $684,611.02 |
DisclosureSEC source: 0001093557-21-000274 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,457 F1 · shares: On September 14, 2021, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,457 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 837 | $638.65 | $534,550.05 |
DisclosureSEC source: 0001093557-21-000263 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,671 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,457 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,301 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-21-000054 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,508 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 13,508 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 8,207 of which were granted on November 19, 2020 and shall vest through November 19 2024. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 22:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 8,207 | $0.00 | $8.21 |
DisclosureSEC source: 0001093557-20-000310 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,207 F1 · shares: Represents a grant of RSUs that vest in four annual installments on November 19, 2021, November 19, 2022, November 19, 2023 and November 19, 2024. Share units represent a contingent right to receive one share of Dexcom, Inc. common stock upon settlement for no consideration. F1 · balance_after: Represents a grant of RSUs that vest in four annual installments on November 19, 2021, November 19, 2022, November 19, 2023 and November 19, 2024. Share units represent a contingent right to receive one share of Dexcom, Inc. common stock upon settlement for no consideration. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 57,153 | Not disclosed Strike: $24.49 | Not disclosed |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · derivative · entry 7 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 57,153 shares Expires 2028-07-24 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 22,241 | Not disclosed Strike: $27.84 | Not disclosed |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · derivative · entry 6 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,241 shares Expires 2029-07-26 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerOrdinary Shares, par value EUR 0.03 per share | 14,462 | $30.75 | $444,706.50 |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · nonDerivative · entry 5 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 14,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · nonDerivative · entry 4 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,462 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerOrdinary Shares, par value EUR 0.03 per share | 17,909 | $30.75 | $550,701.75 |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · nonDerivative · entry 3 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: See Exhibit 99.1. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerOrdinary Shares, par value EUR 0.03 per share | 18,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · nonDerivative · entry 2 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,909 F3 · shares: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4 · balance_after: Includes 16,398 Shares issuable upon vesting of the Wright RSUs and 1,511 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:03 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | OtherOrdinary Shares, par value EUR 0.03 per share | 6,412 | $30.75 | $197,169.00 |
DisclosureSEC source: 0001686266-20-000011 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,099 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 6,412 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2 · balance_after: Includes 16,398 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 19,701 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 16:05 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 1,788 | $30.13 | $53,872.44 |
DisclosureSEC source: 0001235802-20-000100 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,511 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 10,974 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 25,125 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:29 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 19,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-20-000090 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,299 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. The grant agreement contemplates that the shares will vest pro rata through the closing of the previously announced Stryker transaction, and shares unvested at closing will be cancelled. F2 · balance_after: Includes 16,461 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, 26,932 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan and 203 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 16:32 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 15,486 | $30.05 | $465,354.30 |
DisclosureSEC source: 0001235802-20-000011 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,598 F1 · balance_after: Includes 16,461 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, 7,231 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan and 203 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 16:20 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | PurchaseOrdinary Shares, par value EUR 0.03 per share | 10,000 | $21.50 | $215,000.00 |
DisclosureSEC source: 0001235802-19-000101 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,881 F1 · balance_after: Includes 21,947 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, 7,231 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan and 703 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 22,241 | $0.00 Strike: $27.84 | $0.00 |
DisclosureSEC source: 0001235802-19-000096 · primary_doc.xml · derivative · entry 2 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,241 Underlying: Ordinary Shares · 22,241 shares Expires 2029-07-26 F3 · derivative.exercise_date: This option vests with respect to 25% of the shares on July 26, 2020 and with respect to the remaining 75% of such shares over the three-year period thereafter in 36 as nearly equal as possible monthly installments. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:09 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 7,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000096 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,881 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. F2 · balance_after: Includes 21,947 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, 7,231 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan and 703 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 16:34 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 57,153 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0001235802-18-000106 · primary_doc.xml · derivative · entry 2 Regan Barry J. · CIK 0001746313 · Sr. Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,153 Underlying: Ordinary Shares · 57,153 shares Expires 2028-07-24 F2 · derivative.exercise_date: This option vests with respect to 25% of the shares on July 24, 2019 and with respect to the remaining 75% of such shares over the three-year period thereafter in 36 as nearly equal as possible monthly installments. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 16:34 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 21,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-18-000106 · primary_doc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · Sr. Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,947 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F1 · balance_after: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.